The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) hit a new 52-week low and has $8.18 target or 12.00% below today’s $9.30 share price. The 6 months bearish chart indicates high risk for the $344.97M company. The 1-year low was reported on Nov, 1 by Barchart.com. If the $8.18 price target is reached, the company will be worth $41.40M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 381,024 shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 48.75% since March 30, 2016 and is downtrending. It has underperformed by 51.77% the S&P500.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. JP Morgan downgraded it to “Neutral” rating and $22 target price in Wednesday, April 27 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, April 28. The firm has “Hold” rating by Zacks given on Wednesday, August 12. The rating was initiated by RBC Capital Markets with “Outperform” on Monday, November 30.

According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”

Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.04, from 1.06 in 2016Q1. The ratio turned negative, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 1,631 shares. Voya Invest Management Limited Liability, a Georgia-based fund reported 16,941 shares. Grp One Trading Ltd Partnership holds 102,189 shares or 0.02% of its portfolio. Wfg Advsrs Limited Partnership owns 65 shares or 0% of their US portfolio. The New York-based Claar Advsr Lc has invested 0.91% in Dynavax Technologies Corporation (NASDAQ:DVAX). Moreover, Panagora Asset Mngmt has 0.02% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 340,600 shares. Blackrock Group Incorporated Limited accumulated 0% or 16,677 shares. Falcon Point Capital Ltd Llc has 0.05% invested in the company for 21,753 shares. Blair William & Com Il, a Illinois-based fund reported 377,772 shares. Fincl Bank Of New York Mellon last reported 0% of its portfolio in the stock. Dsc L P accumulated 155,000 shares or 1.42% of the stock. Nelson Van Denburg And Campbell Wealth Mgmt Group Ltd Company has 100 shares for 0% of their US portfolio. American Century Cos owns 72,902 shares or 0% of their US portfolio. Polar Cap Limited Liability Partnership has invested 0.1% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). National Bank & Trust Of America De last reported 1.36M shares in the company.

More news for Dynavax Technologies Corporation (NASDAQ:DVAX) were recently published by: Investorplace.com, which released: “Dynavax Technologies Corporation (DVAX) Steals Back Gains on Pending Heplisav …” on October 03, 2016. Investorplace.com‘s article titled: “Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains” and published on September 06, 2016 is yet another important article.

DVAX Company Profile

Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.